The overall number of Covid-19 vaccines administered has risen dramatically, but so has the inequality of the distribution between developed and developing countries.
SK bioscience’s net profit fell more than 70 percent in the third quarter on the slowing demand for Covid-19 vaccines.
SK bioscience applied to the World Health Organization (WHO) for an emergency use listing (EUL) for SKYCovione, the country's first domestically developed Covid-19 vaccine.
SKYCovione, the first domestically developed Covid-19 vaccine, is going into Korean arms starting Monday.
The vaccine maker applied to the European Medicines Agency for conditional use authorization for SKYCovione. This comes just a few days after the company applied for approval from Britain's Medicines and Healthcare products Regulatory Agency.
Korea has its own Covid-19 vaccine. The Ministry of Food and Drug Safety on Wednesday announced the approval of SKYCovione, a Covid-19 vaccine developed by SK bioscience.
SK bioscience's Covid-19 vaccine candidate won approval recommendation from the Central Pharmaceutical Affairs Council (CPAC) under the Ministry of Food and Drug Safety.
SK bioscience said Friday it applied with the Ministry of Food and Drug Safety for use approval for GBP510, its Covid-19 vaccine candidate.
SK Bioscience is trying to find new uses for GBP510, its Covid-19 vaccine candidate, as a booster shot or a vaccine for adolescents.
SK Bioscience signed a 200 billion won ($165 million) deal with the Korea Disease Control and Prevention Agency for the supply of GBP510, its Covid-19 vaccine candidate.
Korea JoongAng Daily Sitemap
